Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Should Look To France To Speed Up Access To Innovative Medicines

Executive Summary

Gilead suggests that the UK could take lessons from France on rapidly making innovative new treatments available after approval.

You may also be interested in...



Reimbursement Rejection On Cost Grounds For “Highly Effective” Trodelvy In England

In a draft decision NICE, the health technology appraisal body for England and Wales, has declined to recommend Gilead’s Trodelvy for triple negative breast cancer patients.

Scotland Okays First ILAP Drugs For Reimbursement

The Scottish Medicines Consortium has recommended Gilead’s Trodelvy, Amgen’s Lumykras and Pfizer’s Lorviqua for use on the Scottish National Health Service.

NICE Board Approves Landmark Changes To Increase Flexibility Of Drug Evaluation Methods And Processes In England

Big changes are in store at UK health technology assessment body NICE aimed at improving the way medicines are assessed.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel